

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT03844061

Status	RECRUITING
Phase	Phase 2
Sponsor	Hospital for Special Surgery, New York
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (5)

- Age greater than or equal to eighteen years and less than or equal to 80.
- Classification of systemic sclerosis (SSc), as defined using the 2013 American College of Rheumatology/European Union League Against Rheumatism classification of SSc.
- Diagnosis of dcSSc, as defined by LeRoy and Medsger.
- Disease duration of less than or equal to 3 years as defined by the date of onset of the first non-Raynaud's symptom.
- A modified Rodnan Skin Score (mRSS) of > 14

Exclusion (30)

- Inability to render informed consent in accordance with institutional guidelines.
- Disease duration of greater than 3 years.
- Patients with mixed connective tissue disease or "overlap" unless the dominant features of the illness are diffuse systemic sclerosis.
- Limited scleroderma.
- Systemic sclerosis-like illness associated with environmental or ingested agents such as toxic rapeseed oil, vinyl chloride, or bleomycin.

... and 25 more (see full listing online)

Locations (1 total)

Hospital for Special Surgery, New York, New York, United States